Amedeo Smart

Free Medical Literature Service

 

Amedeo

Breast Cancer
  Free Subscription

Articles published in
J Nucl Med
    October 2025
  1. MCNALLY LR, Claros-Sorto JC, Bynum RC, Grizzle WE, et al
    Assessment of Breast Tumors Using Multispectral Optoacoustic Tomography in a Surgical Setting.
    J Nucl Med. 2025;66:1597-1604.
    >> Share

  2. KUJAWSKI M, Aniogo E, Wong P, Hui S, et al
    Combination Image-Guided and Antibody-Targeted alpha-Therapy Before Targeted Immunotherapy for Treatment of Solid Tumors.
    J Nucl Med. 2025;66:1605-1611.
    >> Share

    August 2025
  3. RYU J, Han S, Yoo TR, Lee SB, et al
    Diagnostic Performance of (18)F-Fluoroestradiol PET/CT for Axillary Lymph Node Metastasis in Invasive Lobular Carcinoma: A Prospective Feasibility Study.
    J Nucl Med. 2025 Aug 14:jnumed.125.269573. doi: 10.2967/jnumed.125.269573.
    >> Share

  4. HUANG W, Li L, Chao F, Yang Q, et al
    [(64)Cu]Cu-NOTA-EV-F(ab')(2) Enables Same-Day Immuno-PET Imaging of Nectin-4 in Triple-Negative Breast and Urothelial Bladder Cancers.
    J Nucl Med. 2025 Aug 7:jnumed.125.270132. doi: 10.2967/jnumed.125.270132.
    >> Share

  5. ENKE JS, Schuller BW, Glantschnig L, Kircher M, et al
    Biodistribution and Radiation Dosimetry for [(68)Ga]Ga-LNTH-1363S, a Probe Targeting Fibroblast Activation Protein alpha.
    J Nucl Med. 2025;66:1284-1290.
    >> Share

    June 2025
  6. RINNE SS, Vargas DB, Seo S, Veach D, et al
    (225)Ac alpha-Pretargeted Radioimmunotherapy of Human Epidermal Growth Factor Receptor 2-Expressing Breast Cancer.
    J Nucl Med. 2025 Jun 5:jnumed.125.269601. doi: 10.2967/jnumed.125.269601.
    >> Share

  7. MANSUR A, McConathy JE, Stringer-Reasor E, Rocque G, et al
    Quantitative [(89)Zr]Zr-Trastuzumab PET and Diffusion- Weighted MRI for Characterization of Metastatic HER2-Positive Breast Cancer with PET/MRI.
    J Nucl Med. 2025 Jun 5:jnumed.124.268931. doi: 10.2967/jnumed.124.268931.
    >> Share

    May 2025
  8. LYNCH SE, Crawford C, Hunt AL, Sligh LL, et al
    Granzyme B PET Imaging Predicts Response to Immunotherapy in a Diet-Induced Obesity Model of Breast Cancer.
    J Nucl Med. 2025 May 29:jnumed.124.268938. doi: 10.2967/jnumed.124.268938.
    >> Share

  9. YEH R, Pareja F, Shobeiri P, Ross D, et al
    Detection of HER2-Low Lesions Using HER2-Targeted PET Imaging in Patients with Metastatic Breast Cancer: A Paired HER2 PET and Tumor Biopsy Analysis.
    J Nucl Med. 2025 May 8:jnumed.124.269227. doi: 10.2967/jnumed.124.269227.
    >> Share

    April 2025
  10. HACHEY JS, Viray TD, Matasci M, Ravazza D, et al
    Targeting Extra Domain A of Fibronectin to Improve Noninvasive Detection of Triple-Negative Breast Cancer.
    J Nucl Med. 2025 Apr 17:jnumed.124.268859. doi: 10.2967/jnumed.124.268859.
    >> Share

    March 2025
  11. SABAHI Z, Nguyen A, Wong K, Li S, et al
    Diagnostic Potential of (68)Ga-NeoB PET/CT with Estrogen Receptor- and Progesterone Receptor-Positive Breast Cancer Undergoing Staging or Restaging for Metastatic Disease.
    J Nucl Med. 2025 Mar 27:jnumed.124.268896. doi: 10.2967/jnumed.124.268896.
    >> Share

  12. PARIHAR AS, Vaz S, Sutcliffe S, Pant N, et al
    (18)F-Fluoroestradiol PET/CT for Predicting Benefit from Endocrine Therapy in Patients with Estrogen Receptor-Positive Breast Cancer: A Systematic Review and Metaanalysis.
    J Nucl Med. 2025 Mar 13:jnumed.124.269163. doi: 10.2967/jnumed.124.269163.
    >> Share

    February 2025
  13. BABEKER H, Njotu FN, Pougoue Ketchemen J, Monzer A, et al
    (225)Ac/(89)Zr-Labeled N4MU01 Radioimmunoconjugates as Theranostics Against Nectin-4-Positive Triple-Negative Breast Cancer.
    J Nucl Med. 2025 Feb 20:jnumed.124.268387. doi: 10.2967/jnumed.124.268387.
    >> Share

  14. SUN L, Sun Y, Zuo K, Fan L, et al
    Pilot Study of Nectin-4-Targeted PET Imaging Agent (68)Ga-FZ-NR-1 in Triple-Negative Breast Cancer from Bench to First-in-Human.
    J Nucl Med. 2025 Feb 13:jnumed.124.269024. doi: 10.2967/jnumed.124.269024.
    >> Share

  15. SUN Y, Hao Z, Gao H, Yang G, et al
    [(99m)Tc]Tc-MY6349 Probe for Trop2-Targeted SPECT Imaging: From Preclinical to Pilot Clinical Study.
    J Nucl Med. 2025 Feb 13:jnumed.124.268564. doi: 10.2967/jnumed.124.268564.
    >> Share

    January 2025
  16. VAN GEEL JJL, Moustaquim J, Boers J, Elias SG, et al
    Intrapatient 16alpha-[(18)F]Fluoro-17beta-Estradiol PET Heterogeneity as a Prognostic Factor for Endocrine Therapy Response and Survival in Patients with Estrogen Receptor-Positive Metastatic Breast Cancer.
    J Nucl Med. 2025 Jan 23:jnumed.124.268984. doi: 10.2967/jnumed.124.268984.
    >> Share

    December 2024
  17. WEEKS JK, Pantel AR, Gitto SB, Liu F, et al
    [(18)F]Fluorthanatrace PET in Ovarian Cancer: Comparison with [(18)F]FDG PET, Lesion Location, Tumor Grade, and Breast Cancer Gene Mutation Status.
    J Nucl Med. 2024 Dec 5:jnumed.124.267627. doi: 10.2967/jnumed.124.267627.
    >> Share

    October 2024
  18. YOUNG AJ, Pantel AR, Kiani M, Doot RK, et al
    Kinetic Analysis and Metabolism of Poly(Adenosine Diphosphate-Ribose) Polymerase-1-Targeted (18)F-Fluorthanatrace PET in Breast Cancer.
    J Nucl Med. 2024 Oct 30:jnumed.124.268254. doi: 10.2967/jnumed.124.268254.
    >> Share

  19. JANNUSCH K, Umutlu L, Kirchner J, Bruckmann NM, et al
    Impact of (18)F-FDG PET/MRI on Therapeutic Management of Women with Newly Diagnosed Breast Cancer: Results from a Prospective Double-Center Trial.
    J Nucl Med. 2024 Oct 10:jnumed.124.268065. doi: 10.2967/jnumed.124.268065.
    >> Share

  20. RYU J, Hyung J, Han S, Jeong JH, et al
    Impact of (18)F-FES PET/CT on Clinical Decisions in the Management of Recurrent or Metastatic Breast Cancer.
    J Nucl Med. 2024 Oct 3:jnumed.124.267913. doi: 10.2967/jnumed.124.267913.
    >> Share

    September 2024
  21. EISSES B, van Geel JJL, Brouwers AH, Bensch F, et al
    Whole-Body HER2 Heterogeneity Identified on HER2 PET in HER2-Negative, -Low, and -Positive Metastatic Breast Cancer.
    J Nucl Med. 2024 Sep 5:jnumed.124.267636. doi: 10.2967/jnumed.124.267636.
    >> Share

    August 2024
  22. MWANIA MM, Gitau SN, Shah J, Makhdomi K, et al
    Association Between CA 15-3 and (18)F-FDG PET/CT Findings in Recurrent Breast Cancer Patients at a Tertiary Referral Hospital in Kenya.
    J Nucl Med. 2024 Aug 29:jnumed.124.267851. doi: 10.2967/jnumed.124.267851.
    >> Share

    June 2024
  23. PHAM TT, Chenoweth A, Patel N, Banu A, et al
    In Vivo PET Imaging of (89)Zr-Labeled Natural Killer Cells and the Modulating Effects of a Therapeutic Antibody.
    J Nucl Med. 2024 Jun 6:jnumed.124.267876. doi: 10.2967/jnumed.124.267876.
    >> Share

    April 2024
  24. ZHOU W, Halder S, Herwald S, Ghijsen M, et al
    Frequent Amplification and Overexpression of PSMA in Basallike Breast Cancer from Analysis of The Cancer Genome Atlas.
    J Nucl Med. 2024 Apr 25:jnumed.123.266659. doi: 10.2967/jnumed.123.266659.
    >> Share

  25. MOSER R, Pfeiffer S, Cala L, Klein E, et al
    Detecting Metastatic Patterns of Oligometastatic Breast Cancer: A Comparative Analysis of (18)F-FDG PET/CT and Conventional CT Imaging.
    J Nucl Med. 2024 Apr 18:jnumed.123.266925. doi: 10.2967/jnumed.123.266925.
    >> Share

  26. GEBHART G, Keyaerts M, Guiot T, Flamen P, et al
    Optimal [(18)F]FDG PET/CT Cutoff for Pathologic Complete Response in HER2-Positive Early Breast Cancer Patients Treated with Neoadjuvant Trastuzumab and Pertuzumab in the PHERGain Trial.
    J Nucl Med. 2024 Apr 4:jnumed.123.266384. doi: 10.2967/jnumed.123.266384.
    >> Share

    March 2024
  27. ALTENA R, Buren SA, Blomgren A, Karlsson E, et al
    Human Epidermal Growth Factor Receptor 2 (HER2) PET Imaging of HER2-Low Breast Cancer with [(68)Ga]Ga-ABY-025: Results from a Pilot Study.
    J Nucl Med. 2024 Mar 28:jnumed.123.266847. doi: 10.2967/jnumed.123.266847.
    >> Share

  28. SAHIN E, Kus T, Aytekin A, Uzun E, et al
    (68)Ga-FAPI PET/CT as an Alternative to (18)F-FDG PET/CT in the Imaging of Invasive Lobular Breast Carcinoma.
    J Nucl Med. 2024 Mar 14:jnumed.123.266798. doi: 10.2967/jnumed.123.266798.
    >> Share

    February 2024
  29. LEUNG KH, Rowe SP, Sadaghiani MS, Leal JP, et al
    Deep Semisupervised Transfer Learning for Fully Automated Whole-Body Tumor Quantification and Prognosis of Cancer on PET/CT.
    J Nucl Med. 2024 Feb 29:jnumed.123.267048. doi: 10.2967/jnumed.123.267048.
    >> Share


Free Medical Abstracts
Privacy Policy
Sponsors
Share

© Amedeo 1997-2016